Neoadjuvant FOLFIRINOX therapy is associated with increased effector T cells and reduced suppressor cells in pancreatic cancer patients

CONCLUSIONS: Our study reveals that neoadjuvant chemotherapy with FOLFIRINOX enhances effector T cells and downregulates suppressor cells. These data indicate that FOLFIRINOX neoadjuvant therapy may improve immune therapy and clinical outcome in PDAC patients.PMID:34593529 | DOI:10.1158/1078-0432.CCR-21-0998

Source: Clinical Cancer Research - October 1, 2021 Category: Cancer & Oncology Authors: Hui Peng C Alston James Darren R Cullinan Graham D Hogg Jacqueline L Mudd Chong Zuo Rony Takchi Katharine E Caldwell Jingxia Liu DeNardo G David Ryan C Fields William E Gillanders Simon P Goedegebuure William G Hawkins Source Type: research